Overview

Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer

Status:
Withdrawn
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
To determine the dose and schedule of sirolimus when given in combination with panitumumab in adult subjects with Stage IIIB/IV NSCLC
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Everolimus
Panitumumab
Sirolimus